CDC Global Health

FY2016 Funding Recommendation:  
$1.114 billion

 

Funding History

       Enacted   

       President's FY2016 Request   

       InterAction's FY2016 Recommendation


Justification

 Key Facts

  • The CDC is the key partner in the PEPFAR program.

  • The CDC leads the TB Trials Consortium, which includes a global network of tuberculosis clinical trial sites in over eight countries.

  • In addition to tracking and reporting diseases globally, CDC funds critical product development projects for new health technologies.

As one of the world’s premier public health agencies with over 60 years of experience, the CDC works with foreign ministries of health, international organizations, and other partners to strengthen global health capacity, increase security, and support evidence-based global health programs.

CDC global health funding makes critical contributions to global issues while also protecting the health of Americans: tracking diseases worldwide, providing public health leadership, helping ministries of health strengthen their research and laboratory infrastructure, training new health professionals, and conducting research to develop new technologies to combat diseases around the world. This work capitalizes on CDC technical expertise and improves the ability of partner countries to lead in the future.

Center for Global Health: $469 million

The CDC Center for Global Health (CDC CGH) works alongside foreign ministries of health to prevent the spread of disease worldwide. It is a key partner in PEPFAR (the President’s Emergency Plan for AIDS Relief) in over 75 countries, providing technical assistance on scaling up HIV treatment and preventing mother-to-child transmission.

CDC is also a leader in global immunization and disease eradication efforts. Between 1988 and 2010, CDC programs helped reduce new polio cases globally by more than 99%, and the CDC-initiated global campaign to eradicate Guinea worm disease has helped reduce the disease burden from 3.5 million cases per year in 1986, to near eradication today. Additionally, the CDC’s Center for Global Health provided crucial surveillance and epidemiologic analysis before and after the introduction of the breakthrough MenAfriVac® meningitis A vaccine.

Center for Emerging Zoonotic and Infectious Diseases: $644.7 million

Ongoing research and development at the CDC’s National Center for Emerging Zoonotic and Infectious Diseases (NCEZID) includes new rapid diagnostic tests for plague and rabies. NCEZID continuously investigates and responds to disease outbreaks, such as the 2014 Ebola Virus Disease outbreak in West Africa. It also coordinates the implementation of the National Strategy for Combating Antibiotic Resistant Bacteria focused on preventing, detecting, and controlling outbreaks of antibiotic resistant pathogens, such as drug resistant tuberculosis.

InterAction’s combined FY2016 funding recommendation for the CDC CGH and NCEZID’s global health efforts is $1.114 billion. This funding request will help to bolster programs that continue to advance global health breakthroughs and strengthen and protect the health of individuals worldwide. It includes $11.6 million for the CDC’s new Global Health Security Agenda (GHSA). The GHSA will prioritize building a global capacity to detect global health risks rapidly, preventing them when possible, and responding effectively when they occur. The funding will be used to train epidemiologists, expand public health emergency management capacity, and complement CDC’s continued efforts to combat Ebola in West Africa. As the world continues to respond to the Ebola crisis, it is important to ensure continued capacity strengthening of global health systems and their ability to respond to non-Ebola related issues. 

It should be noted that this request does not include the domestic funding requested for the Prevention and Public Health Fund within NCEZID.

Success Story:

Protecting Asia's children from "brain fever"

The historic announcement came on October 9, 2013, The World Health Organization (WHO) gave a critical stamp of approval for a vaccine against Japanese encephalitis (JE). Nicknamed “brain fever,” JE begins like the flu, progresses to a brain infection, and ends by killing about 30% of its victims – mostly children in rural Southeast Asia – and leaving thousands more with permanent brain injuries.

But thanks to a diverse array of cross-sector partners supported in part by the U.S. Centers for Disease Control and Prevention (CDC), millions of parents no longer worry that their children will suffer from this truly devastating disease.

In 2003, PATH and its partners began advancing the availability of a safe, affordable, easy-to-use JE vaccine known as SA 14-14-2. It quickly became clear that the only way to ensure widespread vaccine access would be through supportive global policies, which require a large body of evidence before being put in place.

To support this effort, the CDC funded PATH to develop a JE surveillance program in Cambodia. This not only required establishing new information systems, but also improved diagnostics. With support from the CDC, the WHO established laboratory networks in the hardest hit countries – such as Cambodia – and provided training to help local health workers accurately diagnose JE.

With a growing body of evidence, PATH, the CDC, and other partners carefully pieced together a complex puzzle illustrating the direct impact of SA 14-14-2 on preventing JE. With the full picture in front of them and a high-quality vaccine manufacturer identified, the WHO declared the JE vaccine safe, effective, and well-suited for use in poor countries. As a result, we are closer than ever to the day when all children at risk of JE are protected.

Photo Credit: PATH/Heng Chivoan

 

Choose to Invest:   2017  |  2016  |  2015  |  2014  |  2013  |  2012